ANI Pharmaceuticals Inc (NASDAQ:ANIP) insider Arthur Przybyl sold 40,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $61.83, for a total value of $2,473,200.00. Following the sale, the insider now directly owns 225,706 shares in the company, valued at $13,955,401.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) traded down $2.29 on Thursday, hitting $59.75. The stock had a trading volume of 165,868 shares, compared to its average volume of 146,009. The firm has a market cap of $728.35, a P/E ratio of -594.01 and a beta of 2.75. The company has a quick ratio of 2.39, a current ratio of 3.36 and a debt-to-equity ratio of 1.13. ANI Pharmaceuticals Inc has a fifty-two week low of $42.23 and a fifty-two week high of $74.70.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 EPS for the quarter, topping the consensus estimate of $1.02 by $0.06. The business had revenue of $47.30 million for the quarter, compared to the consensus estimate of $52.55 million. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. ANI Pharmaceuticals’s revenue was up 23.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.84 EPS. sell-side analysts anticipate that ANI Pharmaceuticals Inc will post 5.17 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of ANIP. Northern Trust Corp lifted its holdings in ANI Pharmaceuticals by 5.2% during the 2nd quarter. Northern Trust Corp now owns 112,905 shares of the specialty pharmaceutical company’s stock worth $5,285,000 after buying an additional 5,599 shares in the last quarter. Vanguard Group Inc. lifted its holdings in ANI Pharmaceuticals by 8.1% during the 2nd quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after buying an additional 35,722 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in ANI Pharmaceuticals by 26.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 15,020 shares of the specialty pharmaceutical company’s stock worth $703,000 after buying an additional 3,183 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in ANI Pharmaceuticals during the 3rd quarter worth $226,000. Finally, Chicago Equity Partners LLC lifted its holdings in ANI Pharmaceuticals by 13.8% during the 3rd quarter. Chicago Equity Partners LLC now owns 22,570 shares of the specialty pharmaceutical company’s stock worth $1,185,000 after buying an additional 2,745 shares in the last quarter. 55.95% of the stock is currently owned by hedge funds and other institutional investors.
ANIP has been the topic of several recent analyst reports. BidaskClub downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 24th. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. TheStreet downgraded ANI Pharmaceuticals from a “b” rating to a “c+” rating in a report on Tuesday, February 20th. Zacks Investment Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, Canaccord Genuity set a $77.00 target price on ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $72.25.
COPYRIGHT VIOLATION WARNING: “ANI Pharmaceuticals Inc (ANIP) Insider Arthur Przybyl Sells 40,000 Shares of Stock” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://ledgergazette.com/2018/03/15/ani-pharmaceuticals-inc-anip-insider-arthur-przybyl-sells-40000-shares-of-stock.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.